Vanda Pharmaceuticals Inc. announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses.
